<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03525028</url>
  </required_header>
  <id_info>
    <org_study_id>2017KY-06</org_study_id>
    <nct_id>NCT03525028</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of Metformin to Decrease Glucocorticoids Side Effects in Patients With Autoimmune Uveitis</brief_title>
  <official_title>Multicenter, Randomized, Controlled Clinical Trial Research Evaluating the Use of Combination Therapy of Glucocorticoids and Metformin to Decrease Glucocorticoids Side Effects in Patients With Autoimmune Uveitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking Union Medical College Hospital, Peking University First Hospital and Zhongshan Ophthalmic Center， Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tianjin Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project is designed to evaluating the use of combination therapy of glucocorticoid and
      metformin to decrease glucocorticoid side effects in participants with autoimmune
      uveitis.This study also aims to evaluate the anti-inflammatory and immunosuppressive effects
      of combination therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approval of the study was obtained from the hospital's ethical committee. The study design
      and methodology followed the tenets of Declaration of Helsinki. All participants were
      provided with written informed consent and received a thorough explanation of the study
      design, aims, and the side effect of metformin. This is a multicenter, randomized, controlled
      clinical trial research. According to 1:1 ratio, all participants are randomly divided into
      two groups, the metformin group and placebo group.

      According to the fasting blood glucose (FBG), triglycerides (TG),total cholesterol (TC) and
      body mass index (BMI), the investigators compared experimental group with control group to
      evaluate whether the use of combination therapy of glucocorticoid and metformin decrease
      glucocorticoid side effects in participants with autoimmune uveitis.

      According to best corrected visual acuity (BCVA), anterior chamber and vitreous inflammation,
      fluorescence fundus angiography (FFA), electroretinogram (ERG) and so on, the investigators
      evaluate the anti-inflammatory and immunosuppressive effects of metformin in treatment of
      autoimmune uveitis.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of abnormal metabolic indexes</measure>
    <time_frame>24 weeks</time_frame>
    <description>The assessments of abnormal metabolic indexes include any of these outcome measures: FBG≥6.1 mmol/L, TC≥5.2 mmol/L (200 mg/d1), TG≥1.7 mmol/L (150 mg/dl) or BMI increased 1 kg/m^2 than before in the process of follow-up twice in a row.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">138</enrollment>
  <condition>Uveitis</condition>
  <condition>Metformin</condition>
  <condition>Glucocorticoid</condition>
  <arm_group>
    <arm_group_label>Metformin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral metformin 500 mg once daily for first week, 500 mg twice daily for next 23 weeks. The follow-up treatment according to the participants' condition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral placebo 500 mg once daily for first week, 500 mg twice daily for next 23 weeks. The follow-up treatment according to the participants' condition.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>The investigators assumed that the combination therapy of metformin and glucocorticoids can decrease glucocorticoids side effects and synergia the anti-inflammatory and immune inhibitory effect of glucocorticoids. So the investigators use metformin in the experimental group.</description>
    <arm_group_label>Metformin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The investigators use placebo in the control group.</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Attending Tianjin Medical University Eye Hospital, ophthalmology department of Peking
             Union Medical College Hospital, ophthalmology department of Peking University First
             Hospital and Zhongshan Ophthalmic Center Sun Yat-sen University from January 2018 to
             January 2022.

          2. Chronic and non-infectious autoimmune uveitis with systemic glucocorticoids treatment
             (Initiation dosage ≥ 1 mg/kg/d or ≥ 50 mg/d).

          3. FBG ＜ 6.1 mmol/L, HbAlc＜6.O%, TC ＜5.2 mmol/L(200 mg／d1) and TG ＜1.7 mmol/L(150 mg／dl).

          4. All genders, age ≥ 18 years old.

          5. Ready for systemic glucocorticoids treatment.

          6. Willing to follow all study requirements and sign the informed consent.

          7. Without history of cancer and serious systemic diseases.

        Exclusion Criteria:

          1. Participate in other clinical trials within the preceding one years

          2. Planning ophthalmologic surgery over the next three months.

          3. With other sight-threatening diseases except cataract, such as glaucoma, diabetic
             retinopathy, retinal detachment, and so on.

          4. Taking or will take immunosuppressants which affecting glycometabolism and lipid
             metabolism except methotrexate and azathioprine.

          5. Any known history of a serious infection (e.g., HIV, hepatitis, pneumonia, syphilis or
             tuberculosis).

          6. Any known history of diabetes mellitus, severe hepatic, renal or heart disease.

          7. Any known history of drug addiction, drug abuse and malignant tumor.

          8. Presence of a transplanted solid organ.

          9. Pregnant women and nursing mothers.

         10. Any known history of mental disorders.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaorong Li, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Tianjin Medical University Eye Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaomin Zhang, M.D.</last_name>
    <phone>+86-13920023990</phone>
    <email>xiaomzh@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tianjin Medical University Eye Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Del Barco S, Vazquez-Martin A, Cufí S, Oliveras-Ferraros C, Bosch-Barrera J, Joven J, Martin-Castillo B, Menendez JA. Metformin: multi-faceted protection against cancer. Oncotarget. 2011 Dec;2(12):896-917. Review.</citation>
    <PMID>22203527</PMID>
  </reference>
  <results_reference>
    <citation>Hoes JN, van der Goes MC, van Raalte DH, van der Zijl NJ, den Uyl D, Lems WF, Lafeber FP, Jacobs JW, Welsing PM, Diamant M, Bijlsma JW. Glucose tolerance, insulin sensitivity and β-cell function in patients with rheumatoid arthritis treated with or without low-to-medium dose glucocorticoids. Ann Rheum Dis. 2011 Nov;70(11):1887-94. doi: 10.1136/ard.2011.151464. Epub 2011 Sep 10.</citation>
    <PMID>21908880</PMID>
  </results_reference>
  <results_reference>
    <citation>den Uyl D, van Raalte DH, Nurmohamed MT, Lems WF, Bijlsma JW, Hoes JN, Dijkmans BA, Diamant M. Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction. Arthritis Rheum. 2012 Mar;64(3):639-46. doi: 10.1002/art.33378.</citation>
    <PMID>21953589</PMID>
  </results_reference>
  <results_reference>
    <citation>Schäcke H, Döcke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther. 2002 Oct;96(1):23-43. Review.</citation>
    <PMID>12441176</PMID>
  </results_reference>
  <results_reference>
    <citation>Oray M, Abu Samra K, Ebrahimiadib N, Meese H, Foster CS. Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016;15(4):457-65. doi: 10.1517/14740338.2016.1140743. Epub 2016 Feb 6. Review.</citation>
    <PMID>26789102</PMID>
  </results_reference>
  <results_reference>
    <citation>Gulliford MC, Charlton J, Latinovic R. Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care. 2006 Dec;29(12):2728-9.</citation>
    <PMID>17130214</PMID>
  </results_reference>
  <results_reference>
    <citation>Perez A, Jansen-Chaparro S, Saigi I, Bernal-Lopez MR, Miñambres I, Gomez-Huelgas R. Glucocorticoid-induced hyperglycemia. J Diabetes. 2014 Jan;6(1):9-20. doi: 10.1111/1753-0407.12090. Epub 2013 Oct 29. Review.</citation>
    <PMID>24103089</PMID>
  </results_reference>
  <results_reference>
    <citation>Pasieka AM, Rafacho A. Impact of Glucocorticoid Excess on Glucose Tolerance: Clinical and Preclinical Evidence. Metabolites. 2016 Aug 3;6(3). pii: E24. doi: 10.3390/metabo6030024. Review.</citation>
    <PMID>27527232</PMID>
  </results_reference>
  <results_reference>
    <citation>Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 2005 Jan;1(1):15-25. Review.</citation>
    <PMID>16054041</PMID>
  </results_reference>
  <results_reference>
    <citation>Jeon SM. Regulation and function of AMPK in physiology and diseases. Exp Mol Med. 2016 Jul 15;48(7):e245. doi: 10.1038/emm.2016.81. Review.</citation>
    <PMID>27416781</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2018</study_first_submitted>
  <study_first_submitted_qc>May 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2018</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tianjin Medical University</investigator_affiliation>
    <investigator_full_name>Xiaomin Zhang</investigator_full_name>
    <investigator_title>Director of the Tianjin Medical University Eye Institute，archiater</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uveitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Glucocorticoids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The study protocol,statistical analysis plan,informed consent form and clinical study report are to be shared with other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

